Direkt zum Inhalt
Merck
  • Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.

Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.

Molecular cancer therapeutics (2015-10-24)
Eva Tonsing-Carter, Barbara J Bailey, M Reza Saadatzadeh, Jixin Ding, Haiyan Wang, Anthony L Sinn, Kacie M Peterman, Tiaishia K Spragins, Jayne M Silver, Alyssa A Sprouse, Taxiarchis M Georgiadis, T Zachary Gunter, Eric C Long, Robert E Minto, Christophe C Marchal, Christopher N Batuello, Ahmad R Safa, Helmut Hanenberg, Paul R Territo, George E Sandusky, Lindsey D Mayo, Christine M Eischen, Harlan E Shannon, Karen E Pollok
ZUSAMMENFASSUNG

Triple-negative breast cancers (TNBC) are typically resistant to treatment, and strategies that build upon frontline therapy are needed. Targeting the murine double minute 2 (Mdm2) protein is an attractive approach, as Mdm2 levels are elevated in many therapy-refractive breast cancers. The Mdm2 protein-protein interaction inhibitor Nutlin-3a blocks the binding of Mdm2 to key signaling molecules such as p53 and p73α and can result in activation of cell death signaling pathways. In the present study, the therapeutic potential of carboplatin and Nutlin-3a to treat TNBC was investigated, as carboplatin is under evaluation in clinical trials for TNBC. In mutant p53 TMD231 TNBC cells, carboplatin and Nutlin-3a led to increased Mdm2 and was strongly synergistic in promoting cell death in vitro. Furthermore, sensitivity of TNBC cells to combination treatment was dependent on p73α. Following combination treatment, γH2AX increased and Mdm2 localized to a larger degree to chromatin compared with single-agent treatment, consistent with previous observations that Mdm2 binds to the Mre11/Rad50/Nbs1 complex associated with DNA and inhibits the DNA damage response. In vivo efficacy studies were conducted in the TMD231 orthotopic mammary fat pad model in NOD.Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ (NSG) mice. Using an intermittent dosing schedule of combined carboplatin and Nutlin-3a, there was a significant reduction in primary tumor growth and lung metastases compared with vehicle and single-agent treatments. In addition, there was minimal toxicity to the bone marrow and normal tissues. These studies demonstrate that Mdm2 holds promise as a therapeutic target in combination with conventional therapy and may lead to new clinical therapies for TNBC.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
HEPES, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Monoklonales Anti-β-Aktin in Maus hergestellte Antikörper, clone AC-15, ascites fluid
Sigma-Aldrich
HEPES, BioUltra, for molecular biology, ≥99.5% (T)
Sigma-Aldrich
HEPES-Pufferlösung, 1 M in H2O
Sigma-Aldrich
Monoklonaler Anti-α-Tubulin-Antikörper in Maus hergestellte Antikörper, ascites fluid, clone B-5-1-2
SAFC
HEPES
Sigma-Aldrich
Carboplatin
Sigma-Aldrich
HEPES, BioXtra, suitable for mouse embryo cell culture, ≥99.5% (titration)
SAFC
HEPES
Sigma-Aldrich
HEPES, BioXtra, pH 5.0-6.5 (1 M in H2O), ≥99.5% (titration)
Sigma-Aldrich
Nutlin-3a, ≥98% (HPLC)
Sigma-Aldrich
HEPES, anhydrous, free-flowing, Redi-Dri, ≥99.5%
Sigma-Aldrich
Anti-MDM2-Antikörper, Klon 3G9, clone 3G9, from mouse
Sigma-Aldrich
MISSION® esiRNA, targeting human ARHGAP24
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Arhgap24
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Trp73